Dr Hamilton on the Potential of RLY-2608 in PI3K-Mutated Breast Cancer

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute, discusses the potential of the PI3K inhibitor RLY-2608 in PI3K-mutated breast cancer.

Although the FDA approved the PI3K inhibitor alpelisib (Piqray) in combination with fulvestrant (Faslodex) for patients with estrogen receptor–positive disease in May 2019, the adverse effects (AEs) associated with the combination can make it difficult to administer to some patients, Hamilton explains. Since PI3K is expressed in some normal tissue, treatment with PI3K inhibitors translates to AEs, Hamilton adds.

However, RLY-2608 is designed to be selective for PI3K mutations, avoiding PI3K wild-type or PI3K expressed in normal tissue with more frequency, Hamilton adds. It is hoped that this selectivity will translate to improved efficacy and tolerability for patients with breast cancer harboring PI3K mutations, Hamilton concludes.